NO985194L - Mesylat-dihydratsalter av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2(1H)-indol-2-on(ziprazidone), fremstilling derav og anvendelse derav som dopamin D2 antagonist - Google Patents

Mesylat-dihydratsalter av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2(1H)-indol-2-on(ziprazidone), fremstilling derav og anvendelse derav som dopamin D2 antagonist

Info

Publication number
NO985194L
NO985194L NO985194A NO985194A NO985194L NO 985194 L NO985194 L NO 985194L NO 985194 A NO985194 A NO 985194A NO 985194 A NO985194 A NO 985194A NO 985194 L NO985194 L NO 985194L
Authority
NO
Norway
Prior art keywords
ziprazidone
benzisothiazol
dopamine
piperazinyl
indole
Prior art date
Application number
NO985194A
Other languages
English (en)
Other versions
NO985194D0 (no
NO312514B1 (no
Inventor
Frank Robert Busch
Carol Anne Rose
Russel James Shine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO985194D0 publication Critical patent/NO985194D0/no
Publication of NO985194L publication Critical patent/NO985194L/no
Publication of NO312514B1 publication Critical patent/NO312514B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
NO19985194A 1996-05-07 1998-11-06 Mesylat-dihydratsalter av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1- piperazinyl)-etyl)-6-klor-1,3-dihydro-2(1H)-indol-2-on(ziprazidone), og farmasöytisk blanding for behandling av enpsykotisk forstyrrelse NO312514B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07
PCT/IB1997/000393 WO1997042191A1 (en) 1996-05-07 1997-04-10 Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Publications (3)

Publication Number Publication Date
NO985194D0 NO985194D0 (no) 1998-11-06
NO985194L true NO985194L (no) 1998-11-06
NO312514B1 NO312514B1 (no) 2002-05-21

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19985194A NO312514B1 (no) 1996-05-07 1998-11-06 Mesylat-dihydratsalter av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1- piperazinyl)-etyl)-6-klor-1,3-dihydro-2(1H)-indol-2-on(ziprazidone), og farmasöytisk blanding for behandling av enpsykotisk forstyrrelse

Country Status (40)

Country Link
US (1) US6245765B1 (no)
EP (1) EP0918772B1 (no)
JP (1) JP3494659B2 (no)
KR (1) KR100333215B1 (no)
CN (1) CN1091769C (no)
AP (1) AP765A (no)
AR (1) AR007004A1 (no)
AT (1) ATE278689T1 (no)
AU (1) AU731267B2 (no)
BG (1) BG63544B1 (no)
BR (1) BR9709889A (no)
CA (1) CA2252898C (no)
CO (1) CO4940466A1 (no)
CZ (1) CZ289215B6 (no)
DE (1) DE69731094T2 (no)
DK (1) DK0918772T3 (no)
DZ (1) DZ2222A1 (no)
EA (1) EA001190B1 (no)
EG (1) EG24076A (no)
ES (1) ES2229342T3 (no)
GT (1) GT199700052A (no)
HR (1) HRP970236B1 (no)
ID (1) ID16867A (no)
IL (1) IL126591A (no)
IS (1) IS2080B (no)
MA (1) MA24171A1 (no)
MY (1) MY119997A (no)
NO (1) NO312514B1 (no)
NZ (1) NZ332218A (no)
OA (1) OA10909A (no)
PL (1) PL188330B1 (no)
PT (1) PT918772E (no)
SI (1) SI0918772T1 (no)
SK (1) SK282837B6 (no)
TN (1) TNSN97074A1 (no)
TR (1) TR199802240T2 (no)
TW (1) TW491847B (no)
UA (1) UA46840C2 (no)
WO (1) WO1997042191A1 (no)
ZA (1) ZA973876B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP1698338B1 (en) * 2000-06-02 2008-04-09 Pfizer Products Inc. S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
EP1633400A2 (en) 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
EP1546146A1 (en) * 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
EP1742943A1 (en) * 2005-02-11 2007-01-17 Teva Pharmaceutical Industries Ltd Process of preparing ziprasidone mesylate
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
WO2008143960A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
WO2012053654A1 (en) * 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
ATE236902T1 (de) 1996-05-07 2003-04-15 Pfizer Mesylat des trihydrats des 5-(2-(4-(1,2- benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor 1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist

Also Published As

Publication number Publication date
IS2080B (is) 2006-02-15
DE69731094T2 (de) 2006-02-23
CN1216991A (zh) 1999-05-19
CZ289215B6 (cs) 2001-12-12
KR20000010824A (ko) 2000-02-25
TW491847B (en) 2002-06-21
JP3494659B2 (ja) 2004-02-09
IS4874A (is) 1998-10-20
TNSN97074A1 (fr) 2005-03-15
AP9700976A0 (en) 1997-07-31
AP765A (en) 1999-09-17
HK1017892A1 (en) 1999-12-03
AU731267B2 (en) 2001-03-29
MA24171A1 (fr) 1997-12-31
BR9709889A (pt) 1999-08-10
CA2252898A1 (en) 1997-11-13
BG63544B1 (bg) 2002-04-30
TR199802240T2 (no) 1999-02-22
PT918772E (pt) 2004-12-31
NO985194D0 (no) 1998-11-06
UA46840C2 (uk) 2002-06-17
EP0918772B1 (en) 2004-10-06
DK0918772T3 (da) 2005-01-10
CN1091769C (zh) 2002-10-02
AU2174797A (en) 1997-11-26
CZ349398A3 (cs) 1999-09-15
WO1997042191A1 (en) 1997-11-13
EA001190B1 (ru) 2000-12-25
DE69731094D1 (de) 2004-11-11
ID16867A (id) 1997-11-20
PL188330B1 (pl) 2005-01-31
KR100333215B1 (ko) 2002-06-20
ATE278689T1 (de) 2004-10-15
SI0918772T1 (en) 2005-02-28
EG24076A (en) 2008-05-11
HRP970236A2 (en) 1998-06-30
GT199700052A (es) 2001-08-29
NZ332218A (en) 2005-02-25
AR007004A1 (es) 1999-10-13
SK150898A3 (en) 2000-02-14
SK282837B6 (sk) 2002-12-03
DZ2222A1 (fr) 2002-12-03
NO312514B1 (no) 2002-05-21
HRP970236B1 (en) 2002-12-31
PL329884A1 (en) 1999-04-12
ES2229342T3 (es) 2005-04-16
IL126591A (en) 2001-11-25
IL126591A0 (en) 1999-08-17
OA10909A (en) 2001-10-26
US6245765B1 (en) 2001-06-12
ZA973876B (en) 1998-11-06
EA199800912A1 (ru) 1999-04-29
JPH11509867A (ja) 1999-08-31
BG102892A (en) 1999-09-30
CO4940466A1 (es) 2000-07-24
EP0918772A1 (en) 1999-06-02
MY119997A (en) 2005-08-30
CA2252898C (en) 2003-04-08

Similar Documents

Publication Publication Date Title
NO985194L (no) Mesylat-dihydratsalter av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2(1H)-indol-2-on(ziprazidone), fremstilling derav og anvendelse derav som dopamin D2 antagonist
NO985193D0 (no) Mesylat-trihydrat av 5-(2-(4-(1,2-benzoisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2H-indol-2-on(=ziperasidone), fremstilling derav og anvendelse derav som dopamin-D2-antagonist
NO933093L (no) Monohydrat av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2H-indol-2-on hydroklorid
FI956279L (fi) Menetelmiä ja välituotteita 5-/2-(4-(bentsoisotiatsol-3-yyli)piperatsin-1-yyli)etyyli/-6-kloori-1,3-dihydroindol-2-onin valmistamiseksi
ATE254600T1 (de) Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on
DK1349855T3 (da) 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidin-2,4-dionmesylatsalt
DK1556378T3 (da) Acylderivater af 5-(2-(4-(1,2 benzisothiazol-3-yl)-1piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indo-2-on med neuroleptisk aktivitet
HUP9902404A3 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-choloro-1,3-dihydro-2(2h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
ECSP972089A (es) Sal mesilato trihidrato de 5-[2-[4(1,2-benzoisotiazol-3-il]-1-piperazinil)etil]-6-cloro- 1,3- dihidro- 2h- inddol - 2 - ona